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Background. It has been suggested that chronic hepatitis B infection leads to growth impairment, but data are inconsistent
and underlying factors are not deﬁned. Methods. Children and adolescents with chronic hepatitis B (HBV) or C (HCV) were
retrospectively evaluated for growth, weight, antiviral treatment, biochemical signs of liver inﬂammation, route of infection, and
HBV DNA, respectively. Results. In all, 135 children (mean age 6.1 years, 81 male, 54 female) with HBV (n = 78) or HCV (n = 57)
were studied. Route of infection was vertical in 50%, parenteral in 11%, and unknown in 39%. ALT levels were above 1.5 times
above normal in 30% while 70% had normal/near normal transaminases. 80% were Caucasian, 14% Asian, 1% black, and 4%
unknown. Mean baseline height measured in SDS was signiﬁcantly lower in the study population than in noninfected children
(boys −1.2, girls −0.4, P<0.01). 28 children were below 2 standard deviations of the norm while 5 were above 2 standard
deviations. SDS measures in relation to individual factors were as follows: elevated ALT: boys −1.4, females −0.5 (P<0.01), ALT
normal/near normal: boys +0.4, females +0.6; parenteral transmission: boys −3.3, girls −0.9 (P<0.0 1 ) ,v e r t i c a lt r a n s m i s s i o n :
boys −0.2, females −0.2. Antiviral treatment itself or HBV-DNA load did not reach statistically signiﬁcant diﬀerences. Conclusions.
Chronic HBV or HCV may lead to compromised growth which is mostly inﬂuenced by liver inﬂammation. Our data may argue
for early antiviral treatment in children with signiﬁcant ALT elevation.
1.Introduction
It is estimated that more than half of the world’s population
has been infected with hepatitis B virus (HBV) or hepatitis
C virus (HCV), and 400–550 million people are chronic
carriers. Since both are not cholestatic liver diseases, neither
chronic hepatitis B (CHB) nor chronic hepatitis C (CHC)
have been associated with those liver disorders most likely
to aﬀect the nutritional status and growth of children. A
number of potential causes of malnutrition in chronic liver
diseases have been identiﬁed [1] ,b u tp r e v i o u ss t u d i e sh a v e
suggested that children with chronic hepatitis B or C seem to
be smaller than children without infection [2, 3]. However,
relatively few studies with limited numbers of patients have
evaluated the impact of CHB on children’s growth [2–5].
Moreover, to our knowledge there is no study investigating
growth of children with chronic hepatitis C. Furthermore,
there is little knowledge about the inﬂuence of the speciﬁc
v i r o l o g i c a ls t a t u ss u c ha sh i g ho rl o wv i r a ll o a da n de l e v a t e d
or normal transaminases, the route of infection and antiviral
treatment.
To study the growth of children with CHB or CHC
presents a number of challenges. Since growth itself is a peri-
odic,saltatory,andpulsatileevent,growthdataareinherently
noisy. The inherent noise in growth data is enhanced by the
diﬃculty of obtaining accurate measurements in young chil-
dren at regular intervals, which increases the number of chil-
dren needed for the analysis to reach statistical signifi-cance.
Moreover, if CHB or CHC does impact growth, it is reason-
able to assume that the route of infection, and herewith the
duration of infection, may be a factor in determining height
at a given age. Unfortunately, the date of acquisition of a giv-
en infection is unknown in most cases except children who
are perinatally infected. Finally, growth patterns vary widely
among individuals, and there are notable diﬀerences in
growth patterns between genders and races.
The aim of this study was to determine how CHB or
CHC aﬀects the growth of children. To accomplish this, we
retrospectively monitored the growth and weight of 135
children and tried to identify factors inﬂuencing growth de-
velopment.2 Advances in Virology
Table 1: Baseline characteristics of children infected with hepatitis
Bo rC .
Age (years.)
Median 6.1
Range 0–17
Height (cm)
Median 118.2
Range 50–187.3
Weight (kg)
Median 21
Range 3.1–78.4
Sex (n)
Male 81
Female 54
AST (n)
Elevated > 2 ×UNL 41
< 2 ×UNL 94
Route of Infection
Vertical 68
Parenteral 15
Unknown 52
Race
Caucasien 108
Black 2
Asien 19
Other 6
chronic Hepatitis B n = 78
HBV-DNA (n)
Low∗ 16
High 60
Not determined 2
Treatment HBV (n)
Interferon 7
Lamivudine 14
Interferon, Lamivudine 6
None 51
chronic Hepatitis C n = 57
Treatment HCV (n)
Interferon + Ribavirin 35
None 22
∗HBV DNA < 100.000IU/mL.
2. Patientsand Methods
Pediatric patients in this study are chronically infected with
either hepatitis B or C. They were collected from three cen-
ters: Childrens’ Hospital Essen University, Childrens’ Hospi-
tal Helios Klinikum Wuppertal, and the Childrens’ Hospital
KlinikumimFriedrichheinBerlin.Inaretrospectivestudyall
patients in these hospitals with the diagnosis of chronic HBV
or HCV who were in medical attendance since the year 2000
wereincludedinthisstudy.Thebaselinecharacteristicsofthe
135 children included in this study are shown in Table 1.
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Figure 1: SDS from 135 children with chronic HBV or HCV
infection. 43 children are above and 92 children are below SDS 0.
Each dot represents one patient.
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Figure 2: Comparison of SDS from 135 children with chronic HBV
or HCV infection. ∗P<0.01.
The ethnic origin of our 135 patients is as follows: 63%
are from Eastern Europe, 5% are of Asian origin, 1% are of
African origin, 9% are of Western Europe, and 22% are of
unknown origin. The 28 with signiﬁcant growth retardation
belong to all groups of these diﬀerent regions.
Height and weight were measured in centimetres and kil-
ograms, respectively. The anthropometric results of the last
attendance in our hospital were chosen for each child.
Height and weight, as well as body mass index (BMI)
percentiles,weredeterminedfromthelastvisitofthepatient.
The height data were calculated as SDS for chronological age
using the tables derived from the Dortmunder longitudinal
growth study [6]. Growth was considered to be impaired if
SDS was less than −1.0. Liver inﬂammation was appreciated
by measuring ALT levels. Moreover, other clinical factors asAdvances in Virology 3
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Figure 3: Comparison of SDS from 135 children with chronic HBV or HCV infection in relation to biochemical signs of liver inﬂammation
measured by ALT. ∗P<0.01.
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Figure 4: Comparison of SDS from 135 children with chronic HBV or HCV infection in relation to route of transmission. ∗P<0.01.
antiviral treatment, route of infection, HBV DNA load, race,
sex, and age were evaluated.
In cases of signiﬁcant growth retardation, as in the men-
tioned children, our routine investigations include exclusion
of intestinal malabsorption and exclusion of growth hor-
mone deﬁciency.
The signiﬁcance of intergroup diﬀerences was studied
with SPSS 11.0 computer program by chi-squared test, Wil-
coxon-signed rank and Spearman correlation analysis. A P
value of <0.05 was considered signiﬁcant.
3. Results
TheSDSsforthe135HBV-orHCV-infectedchildrenattheir
last visit in the three study centers are shown in Figure 1, the
medianSDSisshowninFigure 2.Sincetherewasadiﬀerence
between boys and girls, SDS is demonstrated for each group.
The median SDS for both was −0.9 which corresponds to
compromised height regarding a reference population as
published [6]. The height of males tended to be more com-
promised than that of females; however, sex was only of4 Advances in Virology
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Figure 5: Comparison of SDS from 135 children with chronic HBV or HCV infection in relation to treatment. Treatment HCV: interferon
Alpha monotherapy or in combination with ribavirin. Treatment HBV: interferon alpha or lamivudine. n.s., not signiﬁcant.
borderline signiﬁcance. 28 children showed signiﬁcant
growth impairment of more than 2 standard deviations (see
Figure 1).
The most signiﬁcant diﬀerence from the reference pop-
ulation was found after comparing children with normal or
near normal transaminases and those with ALT elevation. In
Figure 3, SDS from children with signiﬁcant ALT elevation is
−1.4 and in those with near normal ALT +0.4 in males and
−0.6 and +0.4 for females, respectively. A similar eﬀect was
found after comparing route of infection (Figure 4): children
with parenteral infection were signiﬁcantly smaller than
those after vertical transmission. We also studied the inﬂu-
ence of HBV DNA load from the 78 HBV-infected children,
but there was no signiﬁcant inﬂuence (data not shown).
Moreover, prior antiviral treatment did not signiﬁcantly
show any diﬀerence (Figure 5). In HBV-infected children,
there was only a tendency that children after treatment with
alpha interferon or lamivudine were slightly taller than those
without treatment. There was no diﬀerence in BMI as only 2
boys, and no girls were below the 3th percentile (Figures 6(a)
and 6(b)).
4. Discussion
In this study, we evaluated the impact of chronic hepatitis B
or C on growth of children and adolescents. We found that
children with HBV or HCV showed compromised growth,
and correlation with clinical variables was able to identify
factors that might play a crucial role for growth abnormal-
ities. In general, high transaminases were associated with
short stature. The second factor that negatively inﬂuenced
growth was parenteral transmission. These two factors are
likely to be linked as children who are infected later in
life (which is usually the case in parenterally transmitted
individuals) are less likely to be in the so-called immuno-
tolerant phase. This phase is a well-described phenomenon
in childhood, and the great majority of children in this
phase are perinatally (vertically) infected. As their immune
system is not yet fully developed, T cells do less harm to in-
fected hepatocytes by cytolytic processes. Therefore, in these
children transaminases are within normal range for years
or even decades until the immunotolerance against HBV
switches to the immune competent phase. In our opin-
ion, it is reasonable that the route of infection and liver
inﬂammation reﬂect the same underlying factor for growth
impairment. However, it has to be noted that in this study
only 15 patients were transmitted parenterally, and therefore
these data need to be conﬁrmed in other trials. Our data
are in line with another study consisting of 72 children with
signiﬁcant ALT elevation who were also found to be smaller
thanothers[3].Incontrast,thereisonereportaboutTurkish
pediatric patients in which no negative eﬀect of hepatitis B
on growth was demonstrated [7]. Due to the low number of
only34immunoactiveand15immunotolerantHBVpatients
involved, this study may have been underpowered. The ﬁnd-
ing of a negative eﬀect of ALT elevation is surprising since
liver biopsies of these children do rarely show signiﬁcant
liver damage [8]. Usually the liver shows no or only mild
inﬂammation. Nevertheless, it seems possible that also mild
but chronic liver inﬂammation is capable to lead to impaired
growth. This explanation is only speculative and it is also
possible, as with other chronic diseases, that the mechanismAdvances in Virology 5
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Figure 6: (a) Percentiles of BMI for boys. (b) Percentiles of BMI for
girls.
underlying compromised growth is multiple and complex.
For example, factors such as decreased caloric intake, malab-
sorption of nutrients, eﬀects of chronic liver disease on IGF
production in the liver or inﬂammatory mediators may con-
tribute to compromised growth in children with HBV or
HCV. However, if veriﬁed in other studies our data provide
one further argument for early antiviral treatment in chil-
dren with biochemical signs of liver inﬂammation despite
histologic mild pathology.
We also searched for the role of HBV itself. According to
our data, the viral load did not inﬂuence growth. In several
other studies with children and chronic viral infection, this
was an important factor: in children with HIV [9], and as-
ymptomatic CMV [10].
Insummary,wefoundthattheaveragechildwithchronic
hepatitis B or C shows compromised growth. Further, we
found that one important factor for growth impairment is
ALT elevations. It is possible that treating HBV- or HCV-
infected children with antiviral drugs may improve their
growth in the long term. Which antiviral treatment (alpha-
interferon or nucleos(t)ide analogues) is the best for long
term development of the child still has to be determined.
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